Overview of Efalizumab Open-label Trials

An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.

Related Videos
Related Content

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.